References
- Jakse G, Algaba F, Malmström P-U, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45:539–46.
- Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:992–1008.
- Schellhammer PF, Ladaga LE, Fillion MB. Bacillus Calmette–Guérin for superficial transitional cell carcinoma of the bladder. J Urol 1986;135:261–4.
- Van der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organizations for Research and Treatment of Cancer trials. J Urol 2000;164:1533–7.
- Andius P, Fehrling M, Holmäng S. Intravesical bacillus Calmette–Guérin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005;96:1290–3.
- Jahnson S, Damm O, Hellsten S, Holmäng S, Liedberg F, Ljungberg B, et al. A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol 2007;43:271–6.
- Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010;58:185–90.
- Herr HW. Restaging transurethral resection of high-risk superficial bladder cancer improves the initial response to bacillus Calmette–Guérin therapy. J Urol 2005;174:2134–7.
- Adiyat KT, Katkoori D, Soloway CT, de los Santos R, Manoharan M, Soloway MS. “Complete transurethral resection of bladder tumor”: are the guidelines being followed? Urology 2010;75:365–7.
- Han KS, Joung JY, Cho KS, Seo HK, Chung J, Park WS, et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 2008;22:2699–704.
- Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66:543–8.
- Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 2007;177:75–9.
- Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette–Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1995;75:552–9.
- Oosterlinck W, Bono AV, Mack D, Hall R, Sylvester R, de Balincourt C, et al. Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. Eur Urol 2001;40:515–17.
- Lebret T, Bohin D, Kassardjian Z, Herve J-M, Molinie V, Barre P, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumours treated with low dose bacillus Calmette–Guérin instillations. J Urol 2000;163:63–7.
- Herr HW. Role of re-resection in non-muscle-invasive bladder cancer. Scientific World J 2011;11:283–8.
- Gaya JM, Palou J, Cosentino M, Patino D, Rodriguez-Faba O, Villavicencio H. A second transurethral resection could not be necessary in all high grade non-muscle-invasive bladder tumours. Actas Urol Esp 2012;36:539–44.